EHA 2019 | Bispecific antibodies in B-ALL; blinatumomab
Robin Foà
• 15 Jun 2019
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses the use of bispecific monoclonal antibodies in B-cell acute lymphoblastic leukemia (ALL). Prof. Foa specifically discusses the use of blinatumomab, which targets CD19 and has recently received clinical approval by the FDA and the EHA. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
